Reports
Gene Delivery Technologies Market Share, Size, Trends, Industry Analysis Report, 2025 - 2034
REPORT DETAILS
Report Code:
PM1857
No. of Pages:
127
Format:
PDF
Published Date:
Base Year:
2024
Author:
Shreyas Shirsat
Historical Data:
2020-2023
REPORT DETAILS
Report Code:
PM1857
Published Date:
No. of Pages:
127
Historical Data:
2020-2023
Format:
PDF
Author:
Shreyas Shirsat
Base Year:
2024
ABOUT THIS REPORT
Gene Delivery Technologies Market Size, Share, Trends, & Industry Analysis Report By Mode (Biological, Chemical, Physical), By Method, By Application, By End User, and By Region – Market Forecast, 2025–2034
Overview
The gene delivery technologies market was valued at USD 5.42 billion in 2024 growing at a CAGR of 11.1% from 2025-2034. Rising demand for gene therapy coupled with growing prevalence of genetic disorders and chronic diseases worldwide is driving the market growth.
Key Insights
- Biological segment led in 2024 due to high adoption of viral vectors.
- Oncology segment expected to grow fastest, driven by cancer gene therapies.
- North America dominated in 2024 with strong biotech infrastructure.
- The U.S. led the region due to high R&D investment and supportive regulations.
- Asia Pacific to grow fastest with rising patient population and awareness.
- China led APAC with government support and biotech investments.
Industry Dynamics
- Rising demand for gene therapy for rare and chronic diseases is driving the adoption of advanced gene delivery solutions.
- Growing prevalence of genetic disorders worldwide is increasing awareness and use of targeted gene delivery technologies.
- High cost of gene therapy development and safety concerns related to viral vectors remain major market challenges.
- Innovations in non-viral vectors, CRISPR therapies, and AI-based delivery systems are opening new avenues for growth.
Market Statistics
- 2024 Market Size: USD 5.42 Billion
- 2034 Projected Market Size: USD 15.50 Billion
- CAGR (2025-2034): 11.1%
- North America: Largest Market Share
Gene delivery technologies provide the possibility of targeted delivery of therapeutic genes to cure genetic disorders and chronic illnesses. These technologies encompass viral and non-viral vectors, CRISPR systems, and RNA therapies, which are frequently combined with digital platforms and AI tools to maximize precision, efficiency, and personalized treatment outcomes.
Increasing demand for gene therapy driven by orphan and chronic conditions, as well as rising prevalence of genetic conditions worldwide, is pushing the adoption of next-generation gene delivery products. Patients and healthcare professionals are increasingly adopting such technologies to improve treatment outcomes and personalized care.
Key players are developing new-generation viral and non-viral vectors, AI-assisted delivery platforms, and CRISPR-based therapies to enhance safety, target specificity and therapeutic effectiveness. For instance, in August 2025, HORIBA and Fujifilm jointly developed a gene delivery system for improved productivity in gene therapy manufacturing for streamlining and up-scaling production of therapeutic genes. Increasing clinical trials, research collaborations with biotech firms and research institutes, and burgeoning market expansion are creating new markets for expansion.
Drivers & Opportunity
Global increase in genetic disorders and chronic diseases: Growing incidence of genetic disorders and chronic diseases is driving demand for novel gene delivery technologies. World Health Organization (WHO) in its latest report states that non-communicable diseases were responsible for 43 million deaths in 2021 and contributed 75% of total deaths worldwide, most of which were early deaths occurring in low- and middle-income countries. Patients increasingly turn to targeted therapies for illnesses such as cystic fibrosis, hemophilia, and muscular dystrophy. Physicians are embracing accurate and effective delivery systems to enhance outcomes. This trend is stimulating investment and speeding up adoption around the globe.
Growing prevalence of genetic disorders worldwide: The rising incidence of genetic disorders is driving the need for safe and efficient gene delivery systems. National Organization for Rare Disorders (NORD) states that approximately 25–30 million Americans, about 10% of the population, suffer from rare diseases that impact fewer than 200,000 people each. Growing awareness of hereditary diseases is driving healthcare systems toward personalized medicine. Non-viral and viral delivery systems are gaining more traction. The growing patient population is propelling the research for next-generation delivery technologies for wider applications.
Segmental Insights
Mode Analysis
In terms of mode, the segment comprises of biological, chemical, and physical. The biological segment dominated the market in 2024, driven by high adoption of viral vector-based gene delivery systems. Moreover, increasing use in treating rare genetic disorders and chronic diseases is reinforcing market growth globally.
The chemical segment is expected to register the highest growth CAGR over the forecast period, owing to increasing innovations in non-viral chemical vectors. Further, better safety profiles and efficacy are boosting adoption in research and clinical applications.
Method Analysis
Based on method, the segmentation includes ex vivo, in vivo, and in vitro. The ex vivo segment led the market in 2024 owing to extensive application in the alteration of patient-derived cells prior to transplantation. Additionally, utility in personalized gene therapy is propelling continuous adoption in hospitals and research institutes.
In vivo segment witnessed the highest CAGR during the forecast period with the growing demand for direct gene delivery to patients. In addition, developments in viral and non-viral vectors are improving therapeutic outcomes globally.
Application Analysis
Based on application, the segmentation includes infectious diseases, oncology, ophthalmology, urology, diabetes, CNS, and others. The infectious diseases segment dominated the market in 2024, driven by the adoption of gene-based vaccines and therapies. Moreover, growing incidence of viral and bacterial infections is encouraging adoption of efficient gene delivery platforms.
The oncology segment is expected to grow at the highest CAGR during the forecast period, driven by growing use of gene therapy in the treatment of cancer. As per the WHO, the worldwide cancer incidence set to rise from 20 million in 2022 to over 35 million by the year 2050, with 9.7 million deaths and 53.5 million five-year or shorter survivors.
End User Analysis
Based on end user, the segmentation includes academic & research institutes, pharmaceutical & biotechnology companies, and other end users. Academic and research institutes dominated the market in 2024 due to extensive use of gene delivery technologies for laboratory and experimental studies. Moreover, funding for genetic research and collaborative programs is boosting segment adoption globally.
The pharmaceutical and biotechnology companies’ segment is projected to grow at the fastest CAGR during the forecast period, supported by increasing development of gene therapies and clinical trials. In addition, strategic partnerships are accelerating commercialization of advanced delivery platforms.
Regional Analysis
North America led the gene delivery technologies market due to high adoption of advanced viral and non-viral delivery systems. Moreover, well-established healthcare infrastructure and strong R&D investments are driving innovation. In addition, supportive government regulations for gene therapy are encouraging market expansion.
The U.S. Gene Delivery Technologies Market Insights
The U.S. dominated the gene delivery technologies industry due to increasing prevalence of genetic disorders and chronic diseases. According to the U.S. National health expenditure data, chronic diseases like heart disease, cancer, and diabetes are the main causes of death and disability in the U.S. and drive USD 4.9 trillion in yearly healthcare costs. Moreover, extensive clinical trial activity and biotechnology investments are promoting gene delivery technology adoption. In addition, favorable reimbursement policies are supporting widespread use in hospitals and research centers.
Europe Gene Delivery Technologies Market Insights
Europe holds the substantial share in the gene delivery technologies market owing to adoption of gene therapies for rare and chronic disorders. Moreover, strong pharmaceutical and biotechnology sectors are supporting technology integration. In addition, increasing clinical trials across major countries are expanding market opportunities.
Asia Pacific Gene Delivery Technologies Market Insights
Asia Pacific is the fastest growing market driven by rising awareness of gene therapies and growing patient population for genetic disorders. Nizam's Institute of Medical Sciences (NIMS) in Hyderabad, India witnessed a 418% increase in genetic disorder cases in the past decade, with 12,042 patients treated for rare genetic ailments in 2024, mainly because of increased awareness and diagnostic capabilities.
China Gene Delivery Technologies Market Insights
China is expanding owing to government programs favoring development in the field of gene therapy. In addition, rising rates of genetic disorders and huge patient population are driving demand. Additionally, partnerships between regional biotech companies and international players are strengthening market growth.
Key Players & Competitive Analysis Report
The market for gene delivery technologies is moderately competitive, with players pushing viral and non-viral delivery platforms through AI implementation, CRISPR-based treatment, and digital tracking systems. Collaboration with research institutes, hospitals, and biotechnology firms also strengthens market reach, scalability, and adoption globally.
Key players in the market for gene delivery technologies are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., Revvity, Inc., QIAGEN N.V., GenScript Biotech Corp., Takara Bio USA, Inc., Promega Corporation, Bio-Techne Corporation, Lonza Group AG, Oxford Biomedica PLC, Sartorius AG, and MaxCyte, Inc.
Key Players
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
- Bio-Techne Corporation
- Danaher Corporation
- GenScript Biotech Corp.
- Lonza Group AG
- MaxCyte, Inc.
- Merck KGaA
- Oxford Biomedica PLC
- Promega Corporation
- QIAGEN N.V.
- Revvity, Inc.
- Sartorius AG
- Takara Bio USA, Inc.
- Thermo Fisher Scientific Inc.
Industry Development
- August 2025: Merck KGaA partnered with Skyhawk Therapeutics in a deal worth up to USD 2 billion to advance RNA-targeting gene delivery technologies for neurological diseases.
- May 2025: GenScript launched a GMP-like mRNA manufacturing platform to accelerate early-stage drug development and gene delivery research.
- April 2025: Thermo Fisher Scientific launched its first U.S. cell and gene therapy collaboration center to advance process development and manufacturing for gene delivery and therapeutic applications.
Gene Delivery Technologies Market Segmentation
By Mode (Revenue, USD Billion, 2020–2034)
- Biological
- Adenovirus
- Retrovirus
- AAV
- Lentivirus
- Other Viruses
- Non-viral
- Chemical
- Physical
By Method (Revenue, USD Billion, 2020–2034)
- Ex vivo
- In vivo
- In vitro
By Application (Revenue, USD Billion, 2020–2034)
- Infectious Diseases
- Oncology
- Ophthalmology
- Urology
- Diabetes
- CNS
- Others
By End User (Revenue, USD Billion, 2020–2034)
- Academic & Research Institutes
- Pharmaceutical & Biotechnology Companies
- Other End Users
By Region (Revenue, USD Billion, 2020–2034)
- North America
- The U.S.
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Netherland
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Malaysia
- South Korea
- Indonesia
- Australia
- Rest of Asia Pacific
- Latin America
- Mexico
- Brazil
- Argentina
- Rest of Latin America
- Latin America
- Saudi Arabia
- UAE
- South Africa
- Israel
- Rest of South Africa
Gene Delivery Technologies Market Report Scope
|
Report Attributes |
Details |
|
Market Size in 2024 |
USD 5.42 Billion |
|
Market Size in 2025 |
USD 6.02 Billion |
|
Revenue Forecast by 2034 |
USD 15.50 Billion |
|
CAGR |
11.1% from 2025 to 2034 |
|
Base Year |
2024 |
|
Historical Data |
2025-2034 |
|
Forecast Period |
2025-2034 |
|
Quantitative Units |
Revenue in USD Billion and CAGR from 2025 to 2034 |
|
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors and Industry Trends |
|
Segments Covered |
|
|
Regional Scope |
|
|
Competitive Landscape |
|
|
Report Format |
|
|
Customization |
Report customization as per your requirements with respect to countries, regions and segmentation. |
FAQ's
The global market size was valued at USD 5.42 billion in 2024 and is projected to grow to USD 15.50 billion by 2034.
The global market is projected to register a CAGR of 11.1% during the forecast period.
North America dominated the gene delivery technologies market in 2024 due to high adoption of advanced gene therapy platforms and strong biotechnology infrastructure.
A few of the key players in the market are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., Revvity, Inc., QIAGEN N.V., GenScript Biotech Corp., Takara Bio USA, Inc., Promega Corporation, Bio-Techne Corporation, Lonza Group AG, Oxford Biomedica PLC, Sartorius AG, and MaxCyte, Inc.
The biological segment was the market leader in 2024, led by widespread application of viral vectors in clinical gene therapy and ongoing investment in research on viral-based delivery.
The oncology segment is projected to grow fastest, supported by increasing clinical trials for cancer gene therapies and rising demand for targeted treatment solutions.
Page last updated on: Jan-2023
Download Sample Report of Gene Delivery Technologies Market
Please fill out the form to request a customized copy of the research report.
